Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England

Abstract

Although there are now widely accepted diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) there are few epidemiological data. A prevalence study was performed in the four Thames health regions, population 14 049 850. The prevalence date was 1 January 1995. Data were from a national consultant neurologist surveillance programme and the personal case series of two investigators. A diagnosis of CIDP was made according to definite, probable, possible, or suggestive diagnostic criteria. A wide diVerence in prevalence rates between the four health regions was noted, probably due to reporting bias. In the South East Thames Region, from which the data were most comprehensive the prevalence for definite and probable cases was 1.00/100 000; the highest total prevalence (if possible and suggestive cases were included) would have been 1.24/100 000. On the prevalence date 13% of patients required aid to walk and 54% were still receiving treatment. (J Neurol Neurosurg Psychiatry 1999;66:677-680)

Cost–utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy

“…In order to assess the long-term comparative cost-effectiveness of IVIg and prednisolone it would be necessary to consider carefully the impact of side effects on quality of life and cost. It is thought that the side effects of IVIg treatment are generally minor [1,22] but there is some dispute regarding their frequency. Brannagan et al [23] found that 59% of patients receiving IVIg suffered some adverse effect and Bertorini et al [24] reported a figure of 81%.…”

“…Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a peripheral nerve disorder which is estimated to effect between one and two people per 100,000 population [1,2]. It is characterised by slow onset of weakness and reduced sensation.…”

Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis

“…Older age groups are more likely to have a chronic progressive course of CIDP, whereas a relapsing-remitting pattern is frequently observed in younger patients [3]. The crude prevalence rate of CIDP in different countries has been reported to range between 0.8 and 7.7 per 100,000 population [4][5][6], and falls in between these extremes (3.58 per 100,000 population) for two North-Western Italian Regions (Piedmont and Valle d'Aosta) [7].…”

Epidemiology of Chronic Inflammatory Demyelinating Polyneuropathy Abroad and in Russia

“…Распро-страненность ХВДП в целом составляет от 1 до 8-9 на 100 тыс. Обычно мужчины заболевают в 2 раза чаще [10,12,13,33,[37][38][39][40][41][42][43].…”